Expanded State Medicaid Access for GIMOTI Achieved highest ever monthly GIMOTI prescription fills in May 2024 Promoted former VP of Finance, Mark Kowieski to Chief Financial Officer SOLANA BEACH, Calif. , June 17, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc.
Evoke commercial booth located at site #737 SOLANA BEACH, Calif. , May 16, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray,
114% year-over-year increase in net product sales 70% prescriber growth in Q1 2024 compared to Q4 2023 Growing sales metrics reaffirms company’s $14M net revenue guidance for 2024 SOLANA BEACH, Calif. , May 14, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc.
Michael Cline, DO., Medical Director Gastroparesis Clinic, Cleveland Clinic to present SOLANA BEACH, Calif. , April 17, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an
SOLANA BEACH, Calif. , March 21, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, announced that Matthew J.
Fiscal year 2023 net product sales from prescriptions totaled approximately $5.2M , a 107% increase from 2022 Company projects $14M in net revenue for 2024 SOLANA BEACH, Calif. , March 14, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused
SOLANA BEACH, Calif. , March 07, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti ® (metoclopramide) nasal spray, today announced that the Company is scheduled to
Potential for Additional $22.5 Million in the Event of Exercise of Common Warrants in Full SOLANA BEACH, Calif. , Feb. 14, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an
SOLANA BEACH, Calif. , Feb. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, announced today that it has priced an
GIMOTI now holds four listed patents with coverage through 2029 SOLANA BEACH, Calif. , Nov. 27, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ®
